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Abstract: Parkinson’s disease (PD) is a neurodegenerative disorder that features progressive, disabling
motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor
symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even
earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances,
and cognitive impairment can present, and they often become a heavy burden for both patients and
caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability
in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and
non-pharmaceutical treatments represent the best therapeutic options to improve quality of life in PD
patients. The aim of the present review is to provide a practical, stage-based guide to pharmacological
management of both motor and non-motor symptoms of PD. Furthermore, warning about drug side
effects, contraindications, as well as dosage and methods of administration, are highlighted here,
to help the physician in yielding the best therapeutic strategies for each symptom and condition in
patients with PD.
Keywords: Parkinson’s disease; motor symptoms; non-motor symptoms; non-pharmacological
therapy; l-dopa; dopamine-agonists; acetylcholinesterase inhibitors; monoamine oxidase inhibitors;
amantadine; anticholinergics
1. Introduction
Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by motor and non-motor
features, due to a progressive loss of dopaminergic neurotransmission in basal ganglia [1]. Decrease of
dopamine-containing neurons within substantia nigra and presence of Lewy bodies inclusions are the
core pathological findings in PD [2].
According to Movement Disorder Society-PD (MDS-PD) criteria [3], the clinical diagnosis of PD
has centered on a defined motor syndrome (Parkinsonism), based on three cardinal motor symptoms
(MS), such as bradykinesia, rigidity, and resting tremor. However, non-motor symptoms (NMS),
which include insomnia [4], depression, anxiety [5], cognitive decline [6], apathy [7], neuropsychiatric
disturbances [8], and autonomic dysfunctions [9], can be present at the onset and during disease
progression. Therefore, PD increasingly compromises quality of life and activities of daily living,
although a high variability in clinical presentation and in disease progression can be observed among
people affected [10]. Thus, the Hoehn and Yahr scale is commonly used to compare groups of patients
and to provide an indicative assessment of disease progression, ranging from stage I (only unilateral
involvement) to stage V (wheelchair bound or bedding) [11]. In an early stage, symptoms are usually
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mild and unilateral with a complete response to treatment. Although symptoms tend to progress and
motor symptoms affect the contralateral side, at first drug response is commonly effective. During the
course of the disease, treatment response decreases, and anti-parkinsonian drugs can potentially induce
side effects. After a prolonged disease duration, patients can develop several NMS for which current
treatments are limited [12]. Previous studies have reported that the mean duration of disease ranges
from 6.9 to 14.3 years and the onset of dementia is the highest predictor of increased mortality [13].
In this review both clinical features of PD, motor and non-motor, are described in association
with disease progression (Table 1). Our aim is to provide an up-to-date review of pharmacological
treatments during different stages of the disease.
Table 1. Main pharmacological treatments for motor and non-motor symptoms in each clinical stage of
Parkinson’s Disease (PD).
Early Stage
Motor Symptoms
l-dopa
Non-Ergot Dopamine agonists (DA) (Pramipexole, Ropinirole, and Rotigotine)
Ergot-derived Dopamine agonists (Bromocriptine, Cabergoline, Pergolide, and
Lisuride)
Monoamine oxidase inhibitors (Selegiline, Rasagiline)
Anticholinergics (Triphexyphenidil)
Amantadine
REM Sleep Behavior Disorder (RBD) ClonazepamMelatonin
Constipation
Prebiotic fibers and probiotics
Macrogol
Lubiprostone
Anxiety
Benzodiazepines
Buspirone
SSRIs
Cognitive Behavioral Therapy
Depression SNRI (such as Venlafaxine)SSRIs
Impulse Control Disorder Dopamine agonists discontinuation
l-dopa dose adjustment
Advanced Stage
Motor Symptoms
COMT inhibitors with l-dopa
Monoamine oxidase inhibitors with l-dopa
Safinamide
Cognitive deficits Acetylcholinesterase inhibitors
Apathy RivastigmineDopamine agonists
Psychotic disturbances Atypical Antipsychotics (Clozapine, Quetiapine)Novel anti-serotonergic antipsychotics (Pimavanserin, eligibly Ondansetron)
Orthostatic hypotension
Droxidopa
Fludrocortisone
Midodrine
Urinary dysfunction
Overactive bladder: Anticholinergics (Oxybutynin, Tolterodine, and Solifenacin)
and Mirabegron
Nicturia: Desmopressin
Complicated Stage
Motor fluctuations
Increased frequency of l-dopa administration
Modified Release of l-dopa
Apomorphine
COMT inhibitors (Opicapone)
l-dopa/Carbidopa intestinal gel
Dyskinesia
Reducing doses of l-dopa and increasing frequency
Amantadine
Add-on therapies (DAs, MAOB-Is, COMT-Is)
Super-off
Naso-gastric administration of l-dopa or Dopamine agonists
Endovenous Amantadine
Apomorphine
Transdermal Rotigotine
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2. Early Stage
Several non-motor symptoms and signs of PD can be observed in the very early stages of
disease [14]. According to staging system of Braak, pathological process of PD may not begin in
substantia nigra pars compacta [15]. Indeed, α-synuclein deposition seems to firstly involve the
anterior olfactory nucleus and dorsal motor nucleus of the vagus. A further subsequent finding
suggests that peripheral autonomic ganglia and unmyelinated lamina-1 spinal cord neurons may also
be involved in the initial pathological phases [16]. These findings are consistent with PD typical early
non-motor features, such as olfactory dysfunction, rapid eye movement (REM) sleep behavior disorder
(RBD), constipation, anxiety, and depression [17].
The quantitative assessment of clinical symptoms and progression of the course is an essential
component of any therapeutic trial in PD (Table 2) [1]. Nowadays, many types of medication are
available for symptomatic treatment of early stages of PD [18,19]. In an early stage, timing and
therapeutic choice depend on patient and disease characteristics. Due to PD variability, it is known
that there is not a single preferred therapy to use. The most relevant patient-related factors are age,
which has important implications in tolerability of certain drug classes, and severity of symptoms,
because antiparkinsonian drug efficacy tends to vary into different classes of pharmacological agents.
Thus, symptom severity categorization should be based on a holistic evaluation, including neurologic
examination and a detailed assessment of how symptoms affect daily functions and quality of life [20].
Table 2. Pharmacological trials in PD: critical evaluation.
Drug Mechanism of Action Endpoints Clinical Evidences Comments
Coenzyme Q10
CoQ10 is a component of
electron transport chain,
which is responsible for
mitochondrial adenosine
triphosphate generation.
It is an antioxidant that leads
to decrease free radical
generation. CoQ10 levels
and redox status have been
shown to be altered in
PD patients
Change in total UPDRS
score (Parts I–III) from
baseline
Neither treatment groups
(1200 mg/d of CoQ10 and
2400 mg/d of CoQ10) have
shown any benefit compared
with the placebo group
CoQ10 is safe and well
tolerated, but there is no
evidence of its clinical
benefit
Creatine
Creatine is converted to
phosphocreatine, which can
transfer a phosphoryl group
to adenosine diphospate
(ADP) to make adenosine
triphosphate (ATP)
Difference in clinical
decline from baseline to
5-year follow-up in two
compared groups
(placebo and 10 g/dL of
Creatine monohydrate)
Creatine has failed to slow
the clinical progression
of PD
These findings do not
support the effectiveness
of Creatine monohydrate
in PD patients
Prasinezumab
(RO7046015/PRX002)
Anti-alpha-synuclein
antibody therapy
Efficacy of intravenous
Prasinezumab versus
placebo over 52 weeks in
early in PD patients.
The effectiveness is
evaluated through
MDS-UPDRS (Parts I–III)
Results not yet available Ongoing (Phase 2)
BIIB054 Anti-alpha-synucleinantibody therapy
Safety and biological
effects of three dosages
of BIIB054 compared
to placebo
Results not yet available Ongoing (Phase 2)
Nilotinib
A c-abl inhibitor used in
chronic myelocytic leukemia,
which seems to decrease
phosphorylation of both
parkin and a-synuclein
Safety and tolerability of
daily oral administration
of Nilotinib
Results not yet available Ongoing (Phase 2)
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Table 2. Cont.
Drug Mechanism of Action Endpoints Clinical Evidences Comments
LRRK2
(leucine rich repeat
kinase 2)
LRRK2 mutation is involved
in inherited PD
Use of LRRK2 antisense
oligonucleotides (ASOs)
to decrease endogenous
levels of LRRK2 and
therefore to reduce
α-synuclein inclusion
Administration of LRRK2
ASOs reduces LRRK2
protein levels and
fibril-induced α-syn
inclusions
LRRK2 ASOs is a
potential therapeutic
strategy for preventing
PD without causing
potential adverse
side effects
Ambroxol
Glucocerebrosidase gene
(GBA) mutations are the
most common genetic risk
factor for PD.
Ambroxol is a secretolytic
agent that seems to increase
glucosylceramidase activity
Safety and tolerability of
Ambroxol in PD patients Results not yet available Ongoing (Phase 2)
Isradipine
Isradipine is a
dihydropyridine calcium
channel blocker
Change in UPDRS score
(Parts I–III) to evaluate
long-term benefits of this
drug
STEADY-PD III study has
recently shown that patients
treated with Isradipine did
not have any difference in
motor symptoms compared
to placebo
Inosine
Inosine is a urate precursor
that increases plasma urate,
which is the main plasma
antioxidant
Rate of change in
MDS-UPDRS I–III total
score over 24 months
No evidence in slowing PD
progression (SURE-PD 3,
a phase 3 clinical trial)
Exenatide
A glucagon-like peptide-1
(GLP-1) receptor agonist. In
a preclinical model of PD, it
has shown to have
neuroprotective and
neurorestorative effects
Improvement in
off-medication
MDS-UPDRS score (Part
III) at 60 weeks
It has recently been
discovered to have beneficial
effects on motor function in
a randomized,
placebo-controlled trial
The difference between
the two groups
(Exenatide versus
placebo) at 60 weeks was
the same UPDRS
decrease at 12 weeks,
suggesting a major
symptomatic effect than
a disease modification
ND0612
Liquid subcutaneous
formulation of
l-dopa/carbidopa delivered
via a pump system
- Assess the long-term
safety and tolerability
-Assess efficacy on daily
OFF time based on home
ON/OFF diaries; on the
motor score and
activities OFF daily
living (ADL) scores of
the UPDRS
Reduced daily OFF time by
2.42 ± 2.62 h and 2.13 ± 2.24
h from baseline
Ongoing (Phases 2 and 3)
CVT-301 l-dopa inhalation powder
Change from Pre-dose in
the UPDRS Part III Score
at 30 min post-dose at 12
weeks for CVT-301 high
dose versus placebo
UPDRS motor score change
from pre-dose to 30 min
post-dose was −5.91 (SE 1.50,
95% CI −8.86 to −2.96) for
the placebo group and −9.83
(1.51; −12.79 to −6.87) for the
CVT-301 84 mg group
(between-group difference
−3.92 (−6.84 to −1.00);
p = 0.0088)
CVT-301 (Inbrija) is
approved for the
intermittent treatment of
OFF episodes in PD
patients treated with
Carbidopa/Levodopa
NCT00660387/LCIG
Levodopa-Carbidopa
intestinal gel (LCIG),
administered by continuous
intra-intestinal infusion
(Duodopa®)
- Change from baseline
to week 12 in average
daily normalized
off-time
- Change from baseline
in average daily
normalized on-time
without troublesome
dyskinesia at week 12
Reduced OFF-time after
12 weeks by 4 h compared to
baseline and 1.91 h
compared to standard oral
formulation.
Reduced OFF time by 4.04 h
in LDIG group vs. 2.14 h in
the standard oral
formulation group
(p = 0.0015)
Increase in on-time without
troublesome dyskinesia
(TSD)
Approved by FDA/EU
No difference in UPDRS
motor scores
2.1. Treatments for Non-Motor Symptoms in the Early Stage
2.1.1. Olfactory Dysfunction
Olfactory dysfunction is a typical symptom complained about in the early stage of the disease.
It seems to affect more than 80% of patients, but only about 40% of them are aware of an impaired
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sense of smell [21]. A recent study has reported that olfactory dysfunction is associated with decreased
dopamine transporter binding in more than 40% of patients [22]. In a small cohort of patients with
idiopathic RBD (iRBD), the presence of smell impairment has been detected as a predictive value for
conversion to PD and to Parkinson disease with dementia (PDD) over 5 years [23].
According to previous studies, hyposmia seems to be related to neuronal loss in cortico-medial
amygdala or to decreased dopaminergic neurons in the olfactory bulb. This disturbance, which
generally affects both nostrils, tends to correlate directly with disease duration and severity [24,25].
Furthermore, smell loss has been related to an increased risk of cognitive decline and it is consequently a
prodromal symptom of PDD onset. Currently, hyposmia cannot be treated by any anti-PD drugs [26,27].
2.1.2. REM Sleep Behavior Disorder (RBD)
RBD is a parasomnia characterized by loss of REM sleep atonia, which results in vigorous, violent
motor jerks, and nocturnal vocalizations in association with vivid dreams [28]. The prevalence of
iRBD is not well known, although about 5%–8% of the Caucasian population aged over 60 years
seems to be affected by this sleep disturbance [29]. RBD occurs in up to 50% of PD patients and it
can precede by several years the onset of synucleinopathies, such as PD, Dementia with Lewy bodies
(DLB), and Multiple system atrophy (MSA) [30]. Some evidence suggests that RBD, which is a potential
predictor of disease severity, can be associated with an akinetic-rigid subtype of PD, characterized
by a more pronounced autonomic dysfunction and an increased risk of cognitive impairment or
dementia [31]. Diagnosis is based on polysomnography (PSG), because other pathological conditions,
such as non-REM parasomnias and obstructive sleep apnea, can mimic RBD [17].
Clonazepam and melatonin are first-line treatments for RBD. Clonazepam is a long-lasting
benzodiazepine, which does not suppress motor tone during REM sleep but prevents dream enactment
behavior onset, through uncertain mechanisms [25]. The treatment dose is 0.5 to 2.0 mg before bedtime
and it is rarely associated with dosage tolerance and side effects (<10% of cases), such as daytime
sedation, worsening of obstructive and central sleep apnea, alopecia, depression, memory impairment,
and gastroesophageal reflux. Thus, Clonazepam is completely or partially successful in up to 90% of
patients with RBD [32,33]. Although it is the most common used drug for RBD, current evidence about
its effectiveness have only been based on observational studies (retrospective cohorts and case-series).
In addition, clinical studies have been conducted with small cohorts of patients and without using
PSG to value treatment response [34].
Melatonin can be prescribed as a first-line therapy for patients with poor tolerance or
contraindications to Clonazepam, such as dementia, obstructive sleep apnea, and an increased
risk of falls [35]. It is a hormone released by the pineal gland in a circadian pattern, whose levels rise
shortly after nightfall reaching a peak in the middle of the night [36]. Thus, its role is to regulate the
sleep-wake-cycle. Treatment should be administered at high doses (2 to 10 g) at bedtime. Melatonin
can be used in monotherapy or as add-on therapy in PD patients with RBD [37,38], as suggested
in previous studies in which doses of this substance have successfully treated RBD with few side
effects [39,40].
A limited number of studies have examined the efficacy of melatoninergic agonists in RBD, such
as Agomelatine, Ralmeteon, and Tasimelton. One case series [41] has reported a positive effect of
agomelatine in three patients with iRBD without adverse effects. Recently, two studies [39,42] have
reported the clinical effectiveness of Ralmeteon, a new melatoninergic agonist, already released in
some countries to treat insomnia. To date, no studies on Tasimelton efficacy for RBD treatment have
been published.
Dopaminergic drugs have demonstrated contrasting profiles of efficacy in RBD. A prospective
case series has reported RBD onset after 1 year of Levodopa (l-dopa) treatment in five out of 15 PD
patients [43]. Another study has reported that PD patients with RBD generally used higher doses
of l-dopa [44] in comparison with those without RBD at the same stage of disease. Pramipexole, in
doses up to 2–4 mg at bedtime, has been shown to be effective in 62%–89% of patients with iRBD, RBD
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associated with mild cognitive impairment, or RBD with mild PD [45,46]. In contrast, another study
has not reported severity or frequency decrease of RBD when pramipexole has been added to a stable
l-dopa dose [47].
Acetylcholinesterase inhibitors (AChEI), such as Donepezil, in doses of 10–20 mg, and Rivastigmine,
in doses up to 6 mg at bedtime, seem to be effective in RBD treatment. The role of AChEI in RBD is
supported by experimental studies which have documented that cholinergic neurons, situated in upper
pontine tegmentum and mesencephalon, become active during REM phase and may regulate REM sleep
and atonia [48,49]. These neurons are involved via direct or indirect inhibitory descending pathway
through the reticular magnocellular tract and glycinergic neurons on the spinal motor neurons [50].
Thus, neurodegenerative processes in PD may induce a dysfunction of this nucleus and its afferent or
efferent pathways, resulting in loss of the normal inhibition of motor neurons [51].
Effects of Memantine on sleep disturbances have been evaluated in a multicenter study,
in which [45] patients with RBD were included. Memantine, a glutamatergic antagonist, might
reduce these disorders, but its validity has been limited by the absence of PSG to support RBD
diagnosis [52]. Sodium oxybate, an agent used to treat narcolepsy, has been documented to be effective
as monotherapy or as add-on therapy in RBD in some cases [53,54]. The role of Cannabidiol (CBD) in
PD with RBD has also been evaluated in a pilot study. CBD, used in doses ranging from 75 to 300 mg
for six consecutive weeks, has shown up to 80% frequency decrease of sleep disturbances [55].
2.1.3. Constipation
Constipation, the most common gastrointestinal disturbance in PD, may occur in up to 29%
of patients [56] and it can be present 20 years before the onset of motor symptoms [57]. Therefore,
disease-related pathophysiological mechanisms and drug side effects have been identified to cause
this gastrointestinal disturbance, although physical weakness and lifestyle risks, such as reduced
fluid intake, may promote its onset [58]. According to recent evidence, prebiotic fibers and probiotics
have been considered efficacious and clinically useful to treat constipation [59]. Macrogol, an osmotic
laxative, is an alternative drug with a good efficacy and safety profile. Lubiprostone, an intestinal
chloride secretagogue, is an oral bicyclic fatty acid derived from prostaglandin E1 that selectively
activates type 2 chloride channels (ClC-2) in the apical membrane of the gastrointestinal epithelium.
It therefore softens stools and increases motility [60]. Currently, its use is not accepted in all countries.
Use of antiparkinsonian drugs for constipation remains a subject of controversial debate. Whereas
some authors have related constipation to dopaminergic treatments [60,61], others have contrarily
suggested that l-dopa might improve gastrointestinal symptoms [62]. Moreover, anticholinergics
drugs are contraindicated in PD patients suffering from constipation [63].
2.1.4. Depression and Anxiety
Depression may precede motor symptoms in 30% of PD patients [64]. It may be explained through
a decreased activity in orbitofrontal and limbic cortices. Moreover, previous studies have documented
a correlation between disease severity and depression [65]. The prevalence of anxiety in PD patients
is 25%–40%, which is generally characterized by panic attacks, phobias, and generalized anxiety
disorder [66]. Approximately 92% of patients tends to manifest anxiety disturbances in association
with depression. It is suggested that it can be related to several neurotransmitter deficits, involving
serotonergic, adrenergic, and dopaminergic systems.
According to a recent update [60], Tricyclic Antidepressants (TCAs) can be considered “possibly
useful” to treat depression. Evidence seems to be insufficient for the use of Amitriptyline, although a
recent review has shown that it seems to be more effective than other antidepressants [67]. Treatment
of PD patients with TCAs may result in psychosis, sedation, and daytime sleepiness as well as in
cognitive dysfunction or delirium when used in patients with PDD. Regarding the use of Selective
Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin-Norepinephrine Reuptake Inhibitors
(SNRIs), Venlafaxine seems to present the best effective profile, although other antidepressants such as
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Citalopram, Sertraline, Paroxetine, and Fluoxetine are considered possibly useful in clinical practice.
As a result of conflicting efficacy data, there are still “insufficient evidence” for all SSRIs reviewed. SSRIs
have been found to present an improved safety profile in comparison with TCAs in studies conducted
in psychiatric populations. SSRIs may worsen PD tremors in up to 5% of patients and occasionally
worsen other features of parkinsonism [68]. In addition, Citalopram, used in a daily dose of more
than 20 mg, may cause a QT interval (QTc) prolongation in patients over 60 years [60]. Moreover,
Serotonin syndrome may occur when SSRIs or SNRIs are used in association with Monoamine oxidase
B inhibitors (MAO-BIs), such as Selegiline and Rasagiline [69]. PD-related depression may also be
treated with second generation non-ergot Dopamine agonists (DA) such as Pramipexole [70]. A new
study has evaluated Rotigotine with negative outcomes. Currently, insufficient evidence is present for
the use of MAO-BIs [60].
Anxiety disturbances in PD patients may contribute to relevant impairments in cognitive functions,
in motor performances, and in quality of life. Pharmacological agents, including benzodiazepines,
Buspirone, and SSRIs, may reduce anxiety. For example, although benzodiazepines (such as
Bromazepam) seem to be effective, their long-term use is associated with confusion, gait disturbance,
and increased risk of falls. However, because of the current lack of evidence in efficacy and safety
profile, pharmacological therapies should be used under careful evaluation [70].
2.1.5. Impulse Control Disorder
Impulse Control Disorder (ICD) (i.e., hypersexuality, gambling, binge-eating, compulsive shopping
or hobbying, punding, and homeostatic hedonism disorders) are more frequent in young, male
patients [71]. ICD main risk factors include dopaminergic replacement therapy, in particular with DAs
(14%–17% of cases), and disease duration [72,73]. In these patients, DA therapy should be discontinued
(or at least reduced until ICD cessation) with proportional l-dopa dose adjustment. However, some
patients could experience DAWS, with mood, autonomic, and sleep disorders, requiring careful
symptomatic management [72].
Other NMS, which can appear in the early stage but are prominent during the progression of
disease, will be later discussed.
2.2. Treatments for Motor Symptoms in the Early Stage
2.2.1. l-Dopa
The most effective treatment of PD still remains l-dopa. The global antiparkinsonian efficacy
of l-dopa is so dramatic and predictable that a positive therapeutic response is used to define the
disease itself. The major issue regarding introducing l-dopa is when to start treatment, considering
the well-known effects of long-term use [74]. It has been largely reported that the premature
therapeutic introduction of l-dopa, especially in young patients, leads to develop long-term side effects
such as dyskinesias and motor fluctuations. For this reason, some authors have recommended the
l-dopa-sparing strategy, which consists of the use of other antiparkinsonian medication in young
PD who are more likely to develop dyskinesias and fluctuations related to long term use of l-dopa.
The reason why l-dopa long term use determines the onset of motor dysfunction might be due to
the toxicity of l-dopa upon dopaminergic neurons. In an in vitro experimental setting, it has been
demonstrated that l-dopa metabolites increase oxidative stress and they are toxic to cultures of
mesencephalic neurons [75]. However, there is no in vivo evidence that l-dopa accelerates disease
progression and, as it was shown by an ELLDOPA (Early versus Later Levodopa therapy in PD
patients) study [76], that patients in l-dopa treatment actually are less impaired even after stopping
medication for a few weeks compared to patients who delay l-dopa therapy. Previous studies have also
documented that dopaminergic depletion is involved in visual dysfunction in PD patients, therefore
l-dopa therapy may improve visual disturbances investigated by electrophysiological tests [77,78].
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l-dopa formulations are generally associated with a peripheral Dopa decarboxylase inhibitors
(more frequently carbidopa or benserazide) in order to inhibit peripheral metabolism of l-dopa.
Slight differences in terms of tolerability are associated with the treatment with l-dopa + benserazide
(Madopar) compared to l-dopa + carbidopa (Sinemet). In a triple-blind trial [79], patients were
allocated at random to treatment with either l-dopa + benserazide ratio 4:1 (Madopar) or l-dopa +
carbidopa ratio 10:1 (Sinemet) using dosage schedules recommended by the manufacturers which they
had to adhere to for 6 months. Results showed that the effect of the two schedules on the parkinsonian
symptoms were equal and they appeared equally fast but the frequency of gastrointestinal side-effects
and involuntary movements seemed higher and more severe for Sinemet than for the Madopar group.
Recently, oxidative stress (OS) has been identified as one of the major factors involved
in dopaminergic degeneration. Several treatments based on antioxidant therapies, such as
vitamin E, creatine, coenzyme Q10, and mitoquinone, have been demonstrated effective in animal
models of PD [80]. Several authors have explored the possibility to reduce OS. For example,
1-O-Hexyl-2,3,5-trimethylhydroquinone (HTHQ) is a potent antioxidative agent, studied in vitro
by Jin Park et al., which seems to be involved in inhibition of l-dopa-induced cytotoxicity because of its
role in modulating reactive oxygen species formation in PC12 cells [81]. Moreover, Nikolova et al. [82]
developed an experimental model using healthy mice and some OS indicators, such as malondialdehyde,
protein carbonyl content and advanced glycation end products, were evaluated in blood plasma.
In this study, healthy mice were divided into four groups: the control group, the group treated only
with l-dopa, and the remaining two groups, which were respectively pre-treated with Ascorbic acid
(400 mg/kg) and Rose Oil (400 mg/kg), two antioxidants. A relevant increase of OS indicators levels in
l-dopa treated mice compared to controls has been shown, whereas the same parameters have been
decreased in both groups pre-treated with anti-oxidant compared to the same controls [82]. These
evidences suggest that antioxidants may have a relevant role in protecting dopaminergic neurons from
l-dopa induced cytotoxicity [83].
2.2.2. Dopamine Agonists
DAs are commonly divided into two groups: ergot and non-ergot-derived agonists. It is
noteworthy to consider that DAs are ineffective in patients without therapeutic responses to l-dopa,
but they might have a role in patients with advanced PD as a treatment for motor complications related
to l-dopa [84]. The use of DAs in advanced PD is discussed separately. Neurologists have debated for
years whether to select l-dopa or DAs as initial therapy in relatively young PD patients. DAs should be
generally avoided in patients over 70 years due to poor tolerability. Furthermore, presence of cognitive
dysfunction at baseline may also influence susceptibility to side effects [82].
2.2.3. Non-Ergot Dopamine Agonists
Three Non-Ergot DAs, such as Pramipexole, Ropinirole, and transdermal Rotigotine, are commonly
used in PD and they have been shown to be effective as monotherapy in patients in an early stage
of the disease [85,86]. Few studies have compared efficacy between various DAs and no significant
difference has been found [87]. Pramipexole immediate release is usually started at 0.125 mg three
times daily. Its dose should be increased gradually by 0.125 mg per dose every 5–7 days. Pramipexole
extended release is usually started at 0.375 mg daily at bedtime, eventually increased by 0.375 mg
every 5–7 days. Commonly, the mean daily dose used is 1.5–4.5 mg. Dose adjustments are required
for renal insufficiency, but the extended-release formulation is not recommended in patients with a
creatinine clearance <30 mL/minute [88]. Ropinirole immediate release is usually started at 0.25 mg
three times daily and it should be increased gradually by 0.25 mg per dose each week for 4 weeks to
a total daily dose of 3 mg. After 4 weeks, its dose may be increased weekly by 1.5 mg a day up to a
maximum total daily dose of 24 mg. The extended release formulation is usually started at 2 mg daily
at bedtime and increased by 2 mg every 5–7 days, up to a maximum of 24 mg. Benefits most commonly
occur in a dose range of 12–16 mg daily. Transdermal Rotigotine is a once-daily patch which is usually
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started at 2 mg/daily and titrated weekly by increasing the patch size in 2 mg/daily increments to a
dose of 6 mg/daily. Transdermal formulations are generally preferred in order to avoid issues such as
renal impairment or inability to swallow whole pills.
Adverse effects caused by DAs are similar to those of l-dopa, including nausea, vomiting,
sleepiness, orthostatic hypotension, confusion, and hallucinations. Peripheral edema is common
during chronic use of DAs but does not occur in patients using l-dopa as monotherapy [87]. Most
side effects can be avoided by initiating treatment with small doses and titrating to therapeutic
levels slowly over several weeks. Moreover, patients’ intolerance of one DA may tolerate another
one. In up to 50% of patients with long-term use, DAs are associated with ICD, such as pathologic
gambling, compulsive sexual behavior, or compulsive buying [89]. Dopamine receptor agonists
decrease prolactin concentration [90]. Thus, a potential decreased milk production is observed in
postpartum women taking these agents, which are contraindicated in women who are breastfeeding.
A recent warning on Pramipexole has been issued regarding its risk of excessive somnolence, which
can occur abruptly, at a dose above 1.5 mg/day [91]. Therefore, PD patients who drive may consider
this adverse effect. Moreover, a DA withdrawal syndrome is described in some PD patients which
abruptly stop taking a DA. A subset of patients experience physical and psychiatric disturbances, such
as agitation, anxiety, diaphoresis, and drug craving, that only respond to DAs repletion. Indeed, these
symptoms are refractory to other antiparkinsonian medications, including l-dopa. This phenomenon,
named Dopamine Agonist Withdrawal Syndrome (DAWS), was firstly described in 2010 by Rabinak
and Nirenberg [92]. In retrospective studies, frequency of DAWS is reported to range from 8% to 19%
of PD patients [93].
2.2.4. Ergot-Derived Dopamine Agonists
Ergot-derived DAs, as bromocriptine, cabergoline, pergolide, and lisuride, are considered a
first-generation class of DAs, rarely used because of recurrent side effects. Therefore, these drugs have
been largely replaced by Non-Ergot DAs. Pergolide and cabergoline have been associated with cardiac,
pulmonary and peritoneal fibrosis and also valvular heart due to chronic use [94]. Those side effects
are uncommon with bromocriptine, which can be used in combination with l-dopa in both early and
late PD.
2.2.5. Monoamine Oxidase Inhibitors
MAO-BIs represent the first step in PD treatment in order to prevent disease progression by their
neuroprotective properties. In the DATATOP trial (Deprenyl and Tocopherol Antioxidative Therapy
of Parkinsonism) [95] Selegiline has shown successful results in order to delay disease progression,
which was calculated by the time until the patients needed potent symptomatic dopaminergic therapy.
Another MAO-BI, Rasagiline, has been shown to have modest symptomatic benefits although its
neuroprotective properties are still debated. In the ADAGIO trial (Attenuation of Disease Progression
with Azilect Given Once-Daily) [96], it has been demonstrated that 1 mg dose of Rasagiline seems
to slow disease progression. However, in a recent metanalysis, effective neuroprotective role of
MAO-BI therapies was controversial and their role in a prodromal or pauci-symptomatic stage of PD is
still debated.
2.2.6. Anticholinergics
Anticholinergics could represent another choice in therapeutic settings, although they represent
less effective anti-parkinsonian agents than DAs. However, they seem to be effective in controlling
tremors and in reducing rigidity [60]. Triphexyphenidil is one of the most commonly used. The stating
dose should be 2 mg three times per day, which can be gradually increased up to 15 mg or more per day.
Regarding the safety profile, because of their well-known neuropsychiatric side effects due to central
receptor antagonism (such as confusion, decrease short term memory, hallucinations, and psychosis)
their use is generally limited to young and cognitively intact patients.
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2.2.7. Amantadine
Although Amantadine has been available for nearly four decades (it was originally marked as an
antiviral agent), little is known about its mechanism of action. It has been thought that Amantadine has
both anticholinergic and anti-glutamatergic properties and for this reason is the only antiparkinsonian
drug that could improve the characteristic l-dopa induced dyskinesias often present in the latter stage
of PD [97]. However, Amantadine can be useful in the first stages of PD even though its effects are
more appreciable in the first months of treatment. Moreover, Amantadine use could be associated
with several side effects such as visual hallucinations, ankle edema, and livedo reticularis, which can
influence therapeutic compliance. The usual dose is 100 mg two times per day but dose adjustment up
to 200 mg two times per day might be allowed.
3. Advanced Stage
During progression of PD, the beneficial effects of early stage therapies may reduce, because
of dopaminergic progressive neuronal loss [15], and therefore management of MS becomes more
complicated. Disabling manifestations of this advanced state include worsening of balance, falls,
increasing compromise of gait, and speech disturbances [11].
Another common symptom in advanced PD is represented by dystonia. Dystonia usually follows
l-dopa therapy administration and it may present with several onset patterns: during wearing off,
at peak dose, or with biphasic timing. Approximately 30% of PD patients, treated with l-dopa, tend
to present “off-dystonia”, especially in the morning before the first l-dopa dose. Differently from
other patterns, off-dystonia is commonly painful, and the foot seems to be the main site of pain [55].
By contrast, peak-dose dystonia tends to involve the neck, face, and upper limbs [98], whereas dystonia
occurring as part of diphasic dyskinesia seems to mainly involve lower limbs. Dystonia, which typically
presents after years of disease, rarely occurs in an early stage, usually related to young-onset PD and to
autosomal recessive genetic parkinsonism forms, such as PARK-PARKIN (PARK2) and PARK-SNCA
(PARK1) mutations [99].
Nonetheless, several non-motor features may appear in the advanced stage, such as hallucinations,
psychosis, dysautonomia, mood disorders, and dementia. Some NMS typically debut years before
MS. However, late stages of PD are featured by adjunctive NMS, which are slighter or less common in
early phases.
3.1. Treatments for Motor Symptoms in the Advanced Stage
In the advanced stage, treatment of MS may take advantage of a combination of more drugs.
Association of tolcapone or entacapone (COMT inhibitors) with l-dopa/dopa decarboxylase inhibitor
produces a prolonged duration of antiparkinsonian action, improving motor function [100]. Many
cases [101,102] of hepato-toxicity have been reported with the use of tolcapone, thus practical implication
of this drug has been revised as “unlikely useful”. Conversely, because of its satisfactory profile,
entacapone represents the drug of choice and the triple association entacapone/l-dopa/carbidopa
has become available in a single formulation (Stalevo). Some trials [103,104] have evaluated its
efficacy to reduce motor fluctuation onset. Due to its tonic stimulation of dopamine receptors in the
striatum, it provides more stable plasma l-dopa levels and may decrease the risk of developing motor
complications (dyskinesias and “on-off” phenomenon). Recently opicapone, a new COMT inhibitors,
has been approved. Two studies [105] (BIPARK 1 and 2), in which opicapone was compared with
entacapone and placebo in more than 250 patients, have examined its efficacy. Indeed, it reduced by 2 h
off-time and increased on-time by 1 h without raising the frequency of dyskinesia, as compared with a
placebo, and this benefit was maintained for at least 1 year of therapy without increasing l-dopa dose.
Another association commonly used in advanced PD is MAO-Is with l-dopa. It is almost
established that MAO-B levels are increased in PD brain as a consequence of gliosis. The blocking of
MAO-B prolongs a high dopamine concentration in basal ganglia reducing the development of late
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complications of l-dopa treatment [106]. More recent evidence [107,108] suggests that MAO-BIs can
slow down disability progression associated with PD, without substantial side effects or increased
mortality. Safinamide is a new molecule characterized by a dual mechanism of action: reversible
inhibition of MAO-B and modulation of glutamate release. Clinical studies have demonstrated its
efficacy to control MS and motor fluctuations in a short term (about 6 months), with benefits lasting up
to 2 years [109]. Furthermore, as a highly selective inhibitor, it hampers both dopamine breakdown and
toxic free radical productions. In a placebo-controlled study [110] the superior benefit of Safinamide
when added to a single DA has been found. It should potentiate dopaminergic activity thanks to
stimulation of the D1 receptor and it could be investigated as a disease-modifying therapy in future
studies because of its anti-glutamatergic properties.
Moreover, AChEI has been tested as a novel strategy to prevent falls. Previously, a study conducted
on the effectiveness of Donepezil has showed a reduction in fall rate when compared with placebo,
although it was characterized by a small cohort of patients and a short duration [111]. A randomized,
double-blind, placebo-controlled, phase 2 trial, has demonstrated the efficacy of Rivastigmine to
improve gait instability and to reduce falls in PD patients, with an acceptable safety profile [112].
However, it is necessary to undertake a larger phase 3 trial to analyze primary outcomes and costs,
although the use of these agents seems to be promising in consideration of the role of cholinergic deficit
in gate and cognitive dysfunction in PD patients.
Regarding dystonia, the introduction of dopamine replacement therapy (l-dopa or DAs) can
determine variable effects, although some evidence has suggested a better response to DAs.
Other agents, such as Baclofen, Carbamazepine, and Benzodiazepines, may be used alone or
in combination [113]. Botulinum neurotoxin, produced by Clostridium botulinum, determines local
muscle weakness; hence, it is the first-line treatment for patients with blepharospasm and cervical
dystonia. It also seems to be effective in laryngeal and limb dystonia [114].
3.2. Treatments for Non-Motor Symptoms in the Advanced Stage
3.2.1. Cognitive Deficits
Cognitive deficits, by definition, should not appear within a year from MS onset (1-year rule),
otherwise DLB diagnosis should be considered [115]. Over years, about 26% of PD patients will present
mild cognitive impairment (MCI) features. PD-MCI is mainly associated with “subcortical” deficits
(i.e., executive and attentional), but also visuospatial, praxis, language, and memory impairment can
be present [116]. Dementia also appears in PD in up to 80% of cases, typically in advanced stages, and
is associated with increased mortality [117].
AchEI (donepezil 5–10 mg daily, galantamine 4–8 mg twice a day, rivastigmine 1.5 mg twice a day
up to 6 mg bid) can improve cognition in PD-MCI and in PDD patients [118]. Rivastigmine efficacy
seems higher, especially in PDD patients, as compared to the other two drugs [60,119]. However,
although AchEI does not seem to significantly increase the rate of falls in these patients, a worsening of
tremor may appear. Donepezil seems to show less adverse effects, as compared to Rivastigmine, and
could be employed in patients with more prominent tremor [120].
Memantine, a N methyl D aspartate (NMDA) glutamate receptor used in Alzheimer’s Disease
(AD), was also investigated as a possible therapy in PD patients. Nevertheless, Memantine treated
patients did not show any significant clinical improvement as compared to controls, in cognition as
well as in other NMS (fatigue, apathy, mood, and quality of sleep) [121,122], so its administration
is not supported by evidence. Some previous studies also assessed the effects of Rasagiline (1 mg
daily) on cognitively impaired PD patients. Conflicting results have been found [123]. Nonetheless,
some benefits, particularly in the executive and attentional functions, were observed in treated
patients [124,125].
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3.2.2. Apathy
Apathy shows in 25%–29% of PD patients, who typically exhibit lack of motivation and interests,
and reduced emotional reactivity [126,127]. Apathy is often confused with drug-resistant depression,
due to their clinical similarity, to the untrained eye. Indeed, the two conditions require different
treatments. Apathy can also be a complication following a subthalamic nucleus deep brain stimulation
(STN-DBS, see later) procedure [128]. Rivastigmine (9.5 mg transdermal patch daily) was proven to be
effective in reducing apathy in non-demented and non-depressed advanced PD patients [128]. DAs as
Piribedil, Ropinirole, and Rotigotine, and the dopamine transporter (DaT) inhibitor methylphenidate
have also demonstrated to improve apathy in post-STN-DBS apathy, in PD patients [128]. However,
ICD is an NMS of PD which can also be triggered by these drugs, so caution is recommended in
their administration. Antidepressant agents are not recommended to treat apathy, which could even
worsen [128].
3.2.3. Psychotic Disturbances
Psychotic disturbances (PsD) are quite common in PD patients. Well-formed complex visual
hallucinations (VHs) represent the most common presentation of PsD, with higher incidence in
advanced PD. Auditory, olfactive, and tactile hallucinations may also occur, less frequently. Paranoid
delusions, Othello’s syndrome, and other kinds of delusions are other possible presentations of
psychosis in PD [128,129]. Several theories have been proposed in order to explain the occurrence
of these phenomena in synucleinopathies, mostly in PD and in DLB. Previous hypothesis included
visual deafferentation (as in Charles-Bonnet’s syndrome), loss of cortical inhibition, adverse effects to
dopamine supplementation, monoaminergic imbalance, and others [130,131]. Nowadays, a complex
model has been proposed, involving different neural networks, namely Thalamocortical dysrhythmia
(TCD) [132].
Pharmacological studies on VHs in synucleinopathies helped in assessing the role of the different
neurotransmitters. Indeed, the importance of dopamine transmission has been significantly reduced in
previous years [133,134]. Therapeutic options for PsD of course include antipsychotic agents. However,
due to severe motor worsening, typical antipsychotics (e.g., haloperidol, chlorpromazine) should be
avoided [135]. On the other hand, atypical antipsychotics seem to be very effective, as a possible
consequence of serotonergic modulation on 5-HT2 receptors. Indeed, Clozapine has always been
considered to be extremely effective in these patients [136]. However, patients receiving Clozapine must
undergo weekly blood count tests. Due to this necessity, Clozapine use is now reserved to second-line
treatment of PsD [137]. Quetiapine (total daily dose ranging from 25 mg up to 150–300 mg) use is
nowadays very common, and this drug is often considered a first choice, due to its high tolerability [60].
Remarkably, the Food and Drug Administration (FDA) has recently warned about the increased
mortality risk in elderly people receiving antipsychotics [138]. Accordingly, antipsychotics should be
employed if strictly necessary.
Other novel antiserotonergic drugs have been approved to treat PsD, thus enhancing the
importance of the serotonergic transmission. Pimavanserin, a selective 5-HT2A serotonin receptor
inhibitor, is in fact recommended (34–40 mg daily) [139], in countries where it is available, due to its
efficacy and tolerability [140,141]. Some preliminary evidence also suggest a role for Ondansetron,
an anti-emetic drug, in PsD treatment [142]. However, patients receiving Quetiapine or Pimavanserin
should undergo an EKG exam, due to risk of QT prolongation [60]. Other neurotransmitters have been
implied in VH onset (acetylcholine, GABA, glutamate) [143]; however, current recommendations do
not include therapeutic options acting on their signaling in PD patients [144,145].
3.2.4. Dysphagia
Dysphagia is a common NMS of PD, typically occurring in late stages of the disease. In fact, early
and prominent dysphagia, as well as other severe bulbar dysfunction signs, represent a red flag for
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PD diagnosis, according to current diagnostic criteria (since it is typically associated with progressive
supranuclear palsy) [3]. Lifetime prevalence of dysphagia in PD is about 80%. Only 20%–40% of
patients are aware of their swallowing difficulties, which can eventually lead to ab ingestis pneumonia,
but also to difficulties in medication intake, malnutrition, and dehydration [146]. Unfortunately,
no specific pharmacological treatment for dysphagia is currently available. However, previous studies
documented improvements in swallowing after starting LD or DAs therapy [147,148].
3.2.5. Dysautonomic Symptoms
Dysautonomic symptoms (DS) occurring in advanced PD include orthostatic hypotension (OH)
and urinary dysfunction (UD). Both symptoms, according to current criteria, should not be clinically
relevant within the first five years of disease; otherwise, MSA diagnosis should be considered [3]. OH is
a major risk factor for falls in PD patients and should be carefully evaluated. Droxidopa 100–300 mg
tid, can improve lightheadedness and orthostatic dizziness as monotherapy or add-on therapy [149].
Other possible pharmacological treatments are Fludrocortisone 0.1–0.2 mg daily or (in some countries)
Midodrine 10 mg tid (second-line treatment) [150]. No particular safety issues have been reported for
Droxidopa, except for cardiovascular comorbidities [151,152]. However, Fludrocortisone could lead
to hypokalemia and should not be administered in patients with heart or renal failure. Midodrine
may cause or worsen urinary retention, instead, which is also common in advanced PD. Moreover,
some degree of supine hypertension can occur with all of these drugs (less frequently with Droxidopa).
Laying with a raised head could help reducing this side effect.
UD prevalence in PD patients ranges from 27% to 64%. Common presentations are overactive
bladder, nocturia and, in later stages, detrusor areflexia. Micturition bradykinesia, detrusor-sphincter
dyssynergia, and incomplete pelvic floor relaxation have also been observed [153]. Notably, TCAs
can worsen voiding deficits in PD patients [60]. Anticholinergics can be used to reduce bladder
hyperreactivity: Oxybutynin (2.5 mg bid, up to a 10–20 mg daily dose), and tolterodine (1–2 mg bid)
are the most widely employed. Solifenacin (5–10 mg daily) is also considered an effective treatment for
an overactive bladder and it is associated with less xerostomia [154]. Caution should be used when
administering these antimuscarinic treatments, due to possible induction or worsening of cognitive
impairment [155].
An alternative therapeutic option for an overactive bladder is represented by Mirabegron (50 mg
daily) [156,157]. This drug acts as an agonist on β3 adrenoceptors and it has no antimuscarinic action,
therefore not impairing cognition. Large phase 3 Randomized Controlled Trials have assessed the
efficacy of Mirabegron monotherapy [158]. No particular recommendations for patients’ age and sex
have been reported, as the molecule appears very well tolerated even for long-term therapy, also due
to the lack of antimuscarinic side effects [157].
Intranasal administration of desmopressin can improve nocturia. However, the risk of severe
adverse effects as cognitive impairment and hyponatremia limits the use of this drug in current clinical
practice [159].
Unfortunately, no effective pharmacological treatments are currently available for the other
PD-related micturition disturbances.
Non-pharmacological treatment options for NMS will be later discussed.
4. Complicated Stage: Pharmacological Treatment for Motor Complications
Motor fluctuations generally develop after 4–6 years of therapy and affect about 50% of PD
patients. Wearing-off is the most common type, but other motor complications, such as dose failure,
beginning of dose worsening, end-of-dose rebound, freezing of gait, and Levodopa-induced dyskinesia
(LID), can also develop during disease progression [160,161]. Several therapeutic strategies have
been adopted to reduce frequency and duration of the so-called off-periods (defined by recurrence
of symptoms or lack of l-dopa effects) but none of these drugs are able to completely control motor
fluctuations and their side effects may limit optimal dosage [162].
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4.1. Motor Fluctuations
Medical treatment of motor fluctuations includes increase of l-dopa doses, increased frequency of
l-dopa administration, use of modified release (MR) l-dopa and other treatments [163], involving DAs,
Amantadine, MAO-Bis, and COMT inhibitors. DAs have not been shown to be effective in improving
off-periods. Conversely, Apomorphine is a very effective DA that can be used both as a “rescue” therapy
for off-periods, in an experimental sublingual formulation, or as a continuous infusion in advanced
PD [164]. Indeed, continuous subcutaneous Apomorphine (Apo) infusion seems to be a valid strategy
to contrast refractory motor complications. Apo is a D1 and D2 receptor DA, whose subcutaneous
delivery improves drug bioavailability and onset of action by avoidance of gastrointestinal transit
time [165]. In an RCT, to date only published in abstract form, patients receiving Apo during their
waking time at up to 8 mg/h experienced a reduction in off-time of 2.47 h compared to placebo after
12 weeks. Moreover, patients had an increase in on-time without troublesome dyskinesia (TSD) [166].
Since chronic subcutaneous Apo infusion during daytime seems to improve sleep quality [167], it has
been suggested that nocturnal infusion may be a well-tolerated and effective treatment to reduce
insomnia and disturbing motor sleep symptoms in the advanced stage [168]. Side effects are usually
transient and manageable, of which gastrointestinal disturbances are the most frequently described
in literature [169]. Nausea and vomiting are frequent for acute intermittent Apo injections, used in
predictable and unpredictable off-periods which requires rapid reversal, whereas they are less common
in continuous infusion [170]. Tolerance to these symptoms develops rapidly [171].
COMT inhibitors have proven to be effective in wearing-off. Moreover, Opicapone seems to be
more powerful, effective, and safer than other COMT inhibitors. It has also the advantage of daily
single administration [172]. Opicapone consistently reduces off-time and increases on-time without
rising dyskinesia frequency [173]. When most of dopaminergic projections from substantia nigra to
striatum are lost, motor complications can occur due to pharmacokinetics of l-dopa itself [174]. In fact,
striatal dopamine levels become strictly dependent on peripheral availability of l-dopa, whose plasma
levels are fluctuating in relation to pulsatile oral administration [175]. Therefore, continuous l-dopa
infusion has proven to be more similar to physiological striatal settings, reducing the occurrence and
severity of dyskinesia and off-time [176]. Several novel l-dopa formulations are under investigation
with innovative routes of administration (intestinal infusion, transcutaneous, or inhaled l-dopa).
ND062L is a transcutaneous formulation of l-dopa/carbidopa in a patch-pump device [177]. CVT-301
is a l-dopa inhalation, used as a “rescue” therapy for sudden off: a single dose of 84mg, administered
in association with oral l-dopa/carbidopa, for early morning off symptoms seems to be well-tolerated
and effective [178,179]. A randomized controlled trial (RCT) has shown that Levodopa-carbidopa
intestinal gel (LCIG), administered by continuous intra-intestinal infusion (Duodopa®), was more
effective than oral l-dopa regarding motor fluctuations. After 12 weeks on LCIG, off-time was
reduced by 4 h compared to baseline and 1.91 h compared to standard oral formulation. Moreover,
there was an increase in on-time without troublesome dyskinesia (TSD) [180]. Since there were no
difference in UPDRS motor scores, it is unlikely that the greater reduction in off-time was attributable
to disproportion in l-dopa dosing [181]. Since LCIG is delivered continuously to the proximal jejunum
via percutaneous gastrojejunostomy (PEG-J), adverse effects are primarily related to surgical procedure
or device, including pump malfunction, obstruction of catheter, tube displacement, and abdominal
pain, usually occurring within the first 2 weeks [182]. Therefore, LCIG is efficacious but requires
specialized monitoring to avoid possible complications [183]. All these therapeutic strategies are
designed to increase LD bioavailability. In addition to l-dopa formulations, other drugs acting with
different mechanisms are under investigation. Tozadenant, an adenosine A2A antagonist, has been
conceived for motor fluctuations. Due to contrasting results, the current role of A2A antagonists in
PD seem to be contradictory [184]. As previously mentioned, Safinamide seems to reduce off-periods
without increasing dyskinesias, although long-term effects require further studies [185].
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4.2. Dyskinesia
Prolonged l-dopa treatment presents a risk up to 45% for developing LID after 4–5 years.
Dyskinesias appear as low-amplitude choreic movements, typically related to peak plasma
concentrations of l-dopa. Their phenomenology can vary from dystonia to ballism and myoclonus,
often becoming very disabling. According to their timing of onset related to l-dopa dosing, dyskinesias
can be classified into peak-dose dyskinesias, off-dyskinesias, and biphasic dyskinesias. Peak-dose
dyskinesias, which are the most common LID, occur generally during the highest plasma l-dopa
concentration (20 min to 2 h after a dose). Off-dyskinesias, often noticed as painful foot dystonia, appear
during off-states and they may be seen at first as “early-morning dystonia” [186]. Biphasic dyskinesias
are less common, presenting both at the beginning and at the end of l-dopa dosing. In biphasic
dyskinesias legs are mainly affected with stereotyped movements and with an evident alteration
of gait. This type of LID develops mainly in male patients with early motor complications [187].
The management of LID remains challenging, requiring a delicate therapeutic balance optimizing
l-dopa doses but with the risk of increased “off” time. Treatment can be based on strategies to
prevent their onset, to modify dopaminergic therapy, and to provide more continuous dopaminergic
stimulation using non-dopaminergic drugs [188].
Peak-dose dyskinesias are mainly treated by reducing single doses of l-dopa and adding Diphasic
dyskinesias are instead the most difficult to treat. An increased dosage of l-dopa may eliminate this
disturbance, but peak-dose dyskinesias usually ensue, therefore a switch to DAs is the most effective
strategy. A range of emerging experimental drugs are currently under development to provide a
better control of LID and other complications [189]. However, a common therapeutic strategy consists
of a gradually decrease of l-dopa in each dose and in an increase l-dopa intake interval. A recent
retrospective study has suggested that a less pulsatile l-dopa treatment with six doses daily was
associated with a low incidence of LID in both early and advanced PD patients [190]. From pulsatile to
continuous, it is also the mechanism at the basis of novel levodopa-carbidopa intestinal gel which has
proven to be effective in reducing off-time and improving on-time without dyskinesia [191].
Different pathophysiological mechanisms may contribute to dyskinesia onset. As well as
sensitization of dopamine receptors, also non-dopaminergic pathways, such as glutamatergic,
serotoninergic and GABAergic, seem to be involved [165]. Since chronic stimulation of dopamine D1
receptors results in hyperactivation of NMDA glutamate receptors in the striatum [191], Amantadine,
a nonselective NMDA antagonist, is considered useful as adjunct to l-dopa therapy for treating
dyskinesias, despite its side effects which include confusion and visual hallucinations [15]. Indeed,
the anti-dyskinetic effect of Amantadine has been supported by several double-blind, placebo-controlled
trials [192,193]. Its long-term effects have also been investigated by Thomas and colleagues, reporting
that Amantadine (300 mg) reduces dyskinesias by approximately 45%, although clinical benefits
disappear by 3–8 months [194]. Thus, this evidence has allowed extended-release preparations
(Amantadine ER) to be developed, recently approved by FDA in August 2017 as the first oral treatment
with a proven benefit for both LID and off-time reduction [195], on the basis of two-phase III trials.
The EASE LID [196] and EASE LID 3 [196] have evaluated safety and efficacy profile of Amantadine
ER 274 mg at bedtime, reporting as adverse events mainly hallucinations, dry mouth, orthostatic
hypotension, dizziness, and peripheral edema. In addition, FDA approved in February 2018 a combined
extended and immediate-release formulation of Amantadine (Osmolex ER), indicated for drug-induced
extrapyramidal reactions. Several other drugs have been tested to treat dyskinesias [197,198], even
antiepileptic agents [199,200]. However, their efficacy was unsatisfactory [201], thus they are not
currently recommended [202,203].
As previously discussed, the serotonin system plays such a major role in dyskinesia pathogenesis
because in advanced stages of PD, serotonergic terminals tend to take up l-dopa and to convert it to
dopamine. Based on this evidence, a phase I/IIa study has demonstrated the anti-dyskinetic effects of
Eltoprazine (5 mg), a selective partial 5-HT1A and 5-HT1B receptor agonist [204].
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4.3. Super-Off and Akinetic Crisis
Other motor complications of advanced PD include super-off states and akinetic crisis. These
conditions share similar clinical features, including marked worsening of UPDRS-motor score, even
as compared to baseline, dysphagia, and autonomic instability [205,206]. However, there are some
important differences. Akinetic crisis may occur even in early PD patients and is not responsive to
l-dopa rescue therapy [207,208]. Akinetic crisis is also featured by DaT-SCAN appearance of “burst
striatum” (BS), which is a sign of undetectable deposition of the tracer, also present in very late stages
of the disease [207,208]. Therapeutic options of super-off states include naso-gastric administration
of l-dopa or DAs, endovenous Amantadine (500 mg/die) [209], Apomorphine (100–200 mg/die), and
transdermal Rotigotine [210,211]. Management of complications, including hyperpyrexia, raise of
CPK, and myoglobin levels and subsequent renal failure, thromboembolism, diffuse intravascular
coagulation, ab ingestis pneumonia, is mandatory [212].
5. Non-Pharmacological Treatments for Motor and Non-Motor Symptoms
Treatment options for PD have conventionally focused on dopamine replacement to provide
symptomatic relief from motor symptoms, but several adverse effects are involved. The development
of new technologies and a better knowledge about the role of educational, psychological, and physical
training and interventions have led to a better management of parkinsonian motor and NMS [213].
We will discuss hereby few of the most important non-pharmacological PD treatments.
5.1. Motor Symptoms
Education of the patients and of their caregivers is probably one of the most relevant parts of PD
management and it should be performed early during disease course [214], to prevent immobilization,
falls, and other complications, as well as to prevent misinformation. Indeed, a multidisciplinary
approach from diagnosis is needed in order to obtain the best outcome in terms of quality of life
and accumulation of disability [215]. Gastroenterologists, pneumologists, geriatricians, as well as
nutritionists and physical therapists, are often needed at late stages of the disease in order to treat
several complications [216]. Nonetheless, an early involvement of these professional figures may
significantly improve management of the disease from the beginning [217].
Physical exercise, including aerobic walking, stretching, and physiotherapy with resistance
exercises could improve gait, balance, and global physical performance in PD patients [217,218].
Specifically, it has been reported that intensive training modalities including stretching and resistance
training could improve muscle strength and mobility, therefore giving a better control of some of
MS [218,219], whereas aerobic activity is also helpful for cardiovascular fitness [220]. Several reports
have also enlightened the improvement of non-motor disturbances from physical activity [216].
Speech therapy has been proposed as a non-pharmacological treatment for parkinsonian
hypophonia and dysarthria. Although a degree of improvement is commonly observed with this
therapy, a Cochrane review found the scientific evidence to be still inconclusive and postulated the
need for a large, well-designed, RCT [221]. Afterwards, a more recent review pointed out the efficacy
of Lee Silverman Voice Treatment (LSVT) LOUD for speech disturbances and, remarkably, also in
swallowing and in facial expression [222].
Deep brain stimulation (DBS) is a well-established treatment in PD. Clinical trials have shown
DBS improves motor symptoms, fluctuations, and quality of life, compared with medical therapy
alone [223,224]. The target is usually in the subthalamic nucleus (STN-DBS) or in the globus pallidus
internus (STN-GPi) with similar motor benefits [225], whereas thalamic DBS is also an option to treat
tremors. Surgical treatment tends to be considered when motor fluctuations and dyskinesias become
disabling, despite motor features continuing to respond to l-dopa. Surgical strategies used to be
evaluated after 10–13 years of PD diagnosis [226]. A multicenter randomized trial has showed quality
of life might be improved after STN-DBS in comparison with optimal medical therapy, if DBS was
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performed in an early stage of disease [227]. Despite the effectiveness of DBS, dopaminergic-resistant
symptoms (i.e., axial symptoms), which poorly respond to this technique [228], can be present.
Therefore, new targets, such as pedunculopontine nucleus, substantia nigra and thalamus, have been
emerging as treatment of motor features [229,230].
Since the last decades, non-invasive brain stimulation (NIBS) has been explored in PD, although
insufficient evidence for its use currently remain. Moreover, transcranial magnetic stimulation (rTMS)
has been used to reduce motor disturbances [231]. It has been reported that high-frequency rTMS
over the primary motor cortex significantly reduce subjective freezing of gait (FOG) and improve gait
performance in a randomized, double-blinded, cross-over study [232]. Despite overall moderate effects
of rTMS, its results are considered variable, likely related to different sites of application, stimulation
frequency, and duration [189].
Transcranial Direct Current Stimulation (tDCS) is another non-invasive stimulation technique,
which adopts weak constant electric currents through the scalp to modulate cortical excitability [233].
A double-blind, cross-over, randomized, sham-controlled study has shown that anodal tDCS on the
primary motor cortex seems to reduce dopamine-resistant FOG in a small sample of PD patients [234].
These results have been recently confirmed [235]. However, further studies are needed to validate
tDCS protocols using a larger sample of patients or an extended intervention duration [2].
Finally, physiotherapy-based exercises seem to be the most common interventions used to improve
motor symptoms when compared with baseline [189].
5.2. Non-Motor Symptoms
As discussed, NMS of PD include several manifestations, ranging from neuropsychiatric to sleep
and autonomic disturbances (see Section 2.1). Few non-pharmacological treatment options have been
considered for NMS; however, evidence is often contrasting.
Cognitive behavioral therapy (CBT) is a type of talk therapy which has been shown to significantly
improve several neuropsychiatric disturbances in PD patients, including anxiety, depression and
ICD [60,236]. CBT is based on identifying distorted thoughts, which produce emotional discomforts, in
order to replace them with better alternatives [237]. This treatment seems to ameliorate self-management
skills improving patient and caregivers’ quality of lives. Therefore, an individualized multimodal
approach using CBT in association with pharmacologic therapies should be considered [60,234].
Some evidence suggests cognitive stimulation therapy (CST) and cognitive rehabilitation as
possible non-pharmacological interventions in PD patients with MCI [60,238]. However, further
investigations are needed to identify the appropriate CST techniques for the various possible patterns
and severity of cognitive impairment, also to improve compliance to the therapy [239].
Regarding autonomic disturbances, ensuring adequate fluid intake is mandatory for preventing
orthostatic hypotension [60], as well as providing increased salt intake [240].
Non-motor fluctuations, sleep-related symptoms, and behavioral disturbances, seem to improve
using DBS, despite no clear evidence [241]. Use of repetitive rTMS has been reported in depression,
although no RCT has supported its use in PD-related depression. Moreover, anodal tDCS over
the left dorsolateral prefrontal cortex seems to improve cognitive impairment in PD patients in a
sham-controlled study [242]. However, a recent review has reported inconclusive outcomes for its use
in PD [243].
6. Disease-Modifying Drugs: Potential Approaches
As recent studies suggested, several pathogenic pathways are involved in PD development,
including genetic mutations, apoptosis, excitotoxicity, oxidative stress, mitochondrial dysfunction,
inflammation, accumulation, and toxicity of a-synuclein [244]. Therefore, several promising agents
targeting different pathways have been explored in order to find neuroprotective therapies to prevent
further neuronal cell loss and disease progression [245].
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Currently, no disease modifying therapy has been licensed in PD yet. Previously mentioned
MAO-BIs, such as Rasagiline and Selegiline, and Safinamide have been evaluated for their
neuroprotective properties. Another agent examined is Coenzyme Q10 (CoQ10), which is an essential
cofactor involved in mitochondrial oxidative phosphorylation, as well as a potent antioxidant.
As mitochondrial dysfunction has been implicated in PD pathogenesis, it has been hypothesized
that CoQ10 might have potential neuroprotective effects. Currently, there is no evidence that this
agent may slow disease progression in early PD [246]. Creatine monohydrate, which is converted
to phosphocreatine and can form adenosine triphosphate (ATP) transferring a phosphoryl group to
adenosine diphosphate (ADP), is also implicated in mitochondrial function. Its study has shown that
creatine had no statistically significant benefit compared with a placebo [247].
Regarding a-synuclein toxicity, multiple processes may be involved, including protein synthesis,
mis-folding, fibril formation and aggregation, degradation, and cell-to-cell transmission. Therefore,
several approaches targeting α-synuclein in PD patients have been proposed [60]. Several studies have
evaluated the effects of monoclonal antibodies directed to different parts of the a-synuclein protein (N-,
mid-, C-terminal, or full-length peptide). Therefore, various human clinical trials using anti-a-synuclein
antibodies have been performed showing a good safety profile and tolerability, and a serum reduction
of free a-synuclein levels and increased free plus antibody-bound levels has been reported [248]. Two
phase 2 RCT are ongoing (RO7046015, the PASADENA trial and BIIB054, the SPARK trial) [245].
Nilotinib, a kinase inhibitor approved for chronic myelogenous leukemia treatment, seems to
be involved in c-Abl inhibition. Its neuroprotective effect is due to a phosphorylation decrease of
both parkin and a-synuclein [249]. Glucocerebrosidase gene (GBA) mutations are the most common
genetic risk factor for PD. Moreover, it has been documented that also PD patients without GBA
mutations can present lower enzymatic levels of glucocerebrosidase (GCase), likely due to a-synuclein
toxicity. Therefore, another potential target might include enzyme replacement therapy. Ambroxol,
a secretolytic agent approved for respiratory diseases, increases glucosylceramidase activity with
effects in preclinical models [250].
Leucine rich-repeat kinase 2 (LRRK2) is one of the most prevalent mutations in inherited PD.
Pharmacological LRRK2 inhibition has been demonstrated to bepromising in blocking α-synuclein
pathology. Indeed, a recent study using LRRK2 antisense oligonucleotides (ASOs) has shown that
decreased endogenous levels of LRRK2 reduces α-synuclein inclusion in order to be a potential
therapeutic strategy for preventing PD [251].
Other agents, which are involved in different pathological pathways, are in advanced phases of
testing in PD patients. Isradipine, approved for hypertension treatment, is a dihydropyridine calcium
channel blocker with a relatively high affinity for Cav1.3 channels. Inhibition of Cav1 channels in
PD seems to reduce cytosolic Ca2+ levels, mitochondrial oxidant stress, and sensitivity to toxins
in neurons [252]. Unfortunately, the STEADY-PD III study has recently shown that patients who
were taking isradipine did not have any difference in MS compared to the placebo [253]. Similar
negative results have been recently obtained in the SURE-PD 3, a phase 3 clinical trial conducted in
order to identify the role of inosine, a urate precursor, in slowing PD progression [245]. Deferiprone
has an important role in oxidative stress because it is a powerful iron chelator [254]. Exenatide,
approved for the treatment of diabetes mellitus type 2, is another agent that has been investigated for its
potential neuroprotective effects [255]. It is a synthetic agonist for the glucagon-like peptide-1 (GLP-1)
receptor, which seems to modulate different cellular processes, enhancing mitochondrial function,
neurogenesis, and synaptic function and reducing inflammation [256]. Moreover, other therapies, such
as caffeine [257], statins [258], nicotine [259], and physical therapy [260], might be available to modify
disease progression. Indeed, although proven neuroprotective elements have not already been found
in PD, different promising agents are currently being investigated.
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7. Conclusions
PD is a disabling neurological disorder, characterized by a wide range of features with motor and
non-motor manifestations. A high variability in response to therapy does not currently allow a single
intervention strategy to be found. The research of biomarkers and prodromal symptoms of disease
remains a primary purpose in order to obtain a long-term impact on disease progression. Moreover,
additional studies focused on pathophysiological mechanisms of PD are required to select successful
treatments, since effective disease modification therapies have not been identified, yet.
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